Disclosures: Brown reports no relevant financial disclosures.
November 03, 2020
30 min listen
Save

Inflammatory Bowel Disease for the Rheumatologist

Disclosures: Brown reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Hear what a rheumatologist should know about IBD!

Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.

  • Intro :11
  • In this episode :20
  • Let’s start with some basics of IBD 4:11
  • If a patient has axSpA, what are the chances they’ll develop IBD? 5:14
  • What about silent disease? 7:32
  • When should we send our SpA patients to a GI specialist? 11:22
  • Two medications: budesonide and mesalamine 13:33

Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com

  • This category of drugs – 5-ASA 16:26
  • NSAIDs 20:02
  • A look at COX inhibitors 23:06
  • Selective inhibition with COX-2 seems to be an attractive option for IBD 28:47
  • Conclusion 29:10

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum

References:

Altomonte L, et al. Clin Rheumatol. 1994;13:565-570.

Dougados M, et al. Joint Bone Spine. 2011;78:598-603.

de Winter JJ, et al. Arthritis Res Ther. 2016;18:196.

El Miedany Y, et al. Am J Gastroenterol. 2006;101:311-317.

Long MD, et al. J Clin Gastroenterol. 2016;50:152-160.

Mayberry J. J Gastrointestin Liver Dis. 2013;22:375-377.

Miao X-P, et al. Curr Ther Res Clin Exp. 2008;69:181-191.

Mielants H, et al. J Rheumatol. 1995;22:2273-2278.

Morris AJ, et al. Lancet. 1991;doi: https://doi.org/10.1016/0140-6736(91)91300-J.

Redfern JS, Feldman M. Gastroenterology. 1989;96:596-605.

Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2006;4:203-211.

Stolwijk C, et al. Ann Rheum Dis. 2015;74:65-73.

Svartz N. Acta Medica Scandinavica. 1942;doi: https://doi.org/10.1111/j.0954-6820.1942.tb06841.x.

Takeuchi K, et al. Clin Gastroenterol Hepatol. 2006;4:196-202.

Tanaka K, et al. Eur J Pharmacol. 2008;603:120-132.

Van Praet L, et al. Ann Rheum Dis. 2013;72:414-417.